Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Patience is a virtue", but how do we ignore the burn rate?
How about replacing it with this one: "Time marches on".
U D Man.
You held out longer than I thought.. :)
I should have asked if you were ST trading or holding more for the LT.
The slow Stoch is oversold, yes, and the 50 day should provide support. If not watch out, IMO.
An article on Alzheimer's research trend:
For years, Alzheimer's researchers have focused on two proteins that accumulate in the brains of people with Alzheimer's and may contribute to the disease: plaques made up of the protein amyloid-beta, and tangles of another protein, called tau.
But for the first time, an Alzheimer's researcher has looked closely at not the two proteins independently, but at the interaction of the two proteins with each other—in the brain tissue of post-mortem Alzheimer's patients and in mouse brains with Alzheimer's disease. The research found that the interaction between the two proteins might be the key: as these interactions increased, the progression of Alzheimer's disease worsened...
http://medicalxpress.com/news/2013-06-alzheimer-interaction-proteins-brain.html#inlRlv
An article on Alzheimer's research trend:
For years, Alzheimer's researchers have focused on two proteins that accumulate in the brains of people with Alzheimer's and may contribute to the disease: plaques made up of the protein amyloid-beta, and tangles of another protein, called tau.
But for the first time, an Alzheimer's researcher has looked closely at not the two proteins independently, but at the interaction of the two proteins with each other—in the brain tissue of post-mortem Alzheimer's patients and in mouse brains with Alzheimer's disease. The research found that the interaction between the two proteins might be the key: as these interactions increased, the progression of Alzheimer's disease worsened...
http://medicalxpress.com/news/2013-06-alzheimer-interaction-proteins-brain.html#inlRlv
What indication did you have that it would pop? Looks like knife-catching.
I wish Dr. Lindquist would join Amicus. She'd be a huge asset, but has her own gig with FoldRx. She did a lot of the early groundbreaking work on Heat Shock Proteins, which are essential chaperones for folding.
http://www.whatayear.org/11_06.html
This article might be of interest.
Note this paragraph:
"..By staying focused on cognitive functions, the companies will steer far clear of the amyloid beta and tau hypotheses that dominate much of the research now underway at companies like Eli Lilly ($LLY). Time and again, though, attempts to slow or stop the effects of the disease by clearing toxic proteins has failed, or proved dangerous to patients. So far, the few therapies that are available for the disease do little to help patients, leaving an enormous void that Big Pharma has tried to capitalize on."
http://www.fiercebiotech.com/story/alzheimers-investigators-launch-big-phiii-program-lundbeck-otsuka-drug/2013-10-10?utm_medium=nl&utm_source=internal
To your point, the NIH put out a statement this year that they want drug companies to focus on trials that enroll Alzheimer's patients who at an earlier stage of the disease. Trials using later stage patients are doomed from the start because their condition is too advanced to show efficacy of treatment.
Anyone can take a simple genetic test (saliva) to ID those who have two copies of the APOE4 gene that is linked higher rates of Alzheimer's. 23andme does the test for $99, for example which tests for this and many other diseases. So a genetic test can ID the potential genetic risk for developing the disease, LymPro can quantify the degree of advancement using the Tau biomarker (not sure if it also tests for Beta Amyloids).
The Banner Institute just received funding to conduct a long term study of people between the ages of 60 and 75 who have two copies of this gene.
I went through Jason's tweets looking for this too and did not see it either.
That's not my understanding.
As was mentioned, ZLCS just went through this to keep from being delisted on the NASD. Their share price was struggling to get above $1, so the company pulled the trigger and did a reverse split.
There are two issues: major dilution if the price gets to .10 or above, and a reverse split to get the share price high enough to qualify for uplisting. So keeping the share price over a buck will be imperative if an uplisting happens. They will need to sustain a minimum share price, unlike on the OTC.
Getting back to ZLCS, they had to have their share price over $1.00 for 10 consecutive days or face delisting. They did a 1:6 reverse split which put it over $8 very briefly, but has settled below $5 currently.
I am planning on them doing a reverse split at some point, probably when and if they announce good news with LymPro to mitigate what they have to do to uplist, so this could get messy.
The take away is that shareholders hit a brick wall if it reaches .10 which is when the extra shares become OS. So sell at .099 and buy back after dilution.
You may want to spend time reading the documented evidence of gold manipulation in the markets. Its a foregone conclusion for those familiar with it. GATA.org has done a stellar job laying this out.
I would suggest signing up for their Daily Digest newsletter. Anyone investing in gold and silver should be aware of what is and has been going on for some time.
http://www.gata.org/taxonomy/term/21
wayne
Usually when a company is traumatized like this one, going sub penny, they change their name or merge if they can.
One thing I feel confident about, they will not go forward with their current name. Its too tainted in the market with bad fundamentals.
Personally I think the science has moved away from Beta Amyloids and gone to Tau. Amyloids was a dry hole that absorbed a lot of research money with little to show for it. Confidence in the theory HAD to take a hit. Just my personal take.
This makes me nervous based on an experience AMBS had last year with shorting on the Berlin exchange. They had to sue to get their company "delisted" from that exchange and they never listed it there! It just appeared there one day and a lot of shorting activity was originating from there. From what I gathered at the time, the Berlin exchange seems to have a notorious reputation for its shorting activity.
If its only effective on those under age 16, what percentage of the sickle cell population is that? Whats the size of this market segment?
Don't you mean dumb hands to dumber hands? LOL.
The list of bad CEOs and at at big companies is long.
http://www.businessinsider.com/the-worst-ceos-in-american-history-2010-5?op=1
Then there is the endemic problem of boards rubber stamping the CEO's decisions. They know what side their bread is buttered and usually owe their jobs to the boss.
What does playing sports have to do with making him a better CEO? Its irrelevant, unless you want to tell me it "teaches us how to work together" some other lame etherial principle.
JPetrol, I expected more from you.
Gerald speaks of dilution like Congress talks about cutting spending. Don't hold your breath. I guess I've learned not to believe what people say, but learned to watch what the DO.
I'm not convinced that the board or advisors at AMBS works as you laid out. We've all seen companies who are dysfunctional.
A RS is a foregone conclusion, at least in my mind. That's why I won't buy anymore. Investors want the share price to move. They need Beta for appreciation, but with that many shares OS the share price will be stuck in mud. I expect a RS right after good news, like licensing LymPro.
What? You go public you do it right or don't bother until you can do it right with enough money and a stellar CEO. And which one of these great advisors advised them to let Gerald be the CEO without even a stint as a CEO ANYWHERE before? So much for their advise.
"Unproven" is the word retiredtech, thank you.
Anyone ever try to get a loan for a business? Good luck if you have little or no experience in the field. First thing they want to know is what experience do you have running this kind of business? Same thing with institutional investors. If they invest in a company that is weak in the executive/administrative area and the company blows up, its their tail so they want to see a proven exec at that position to cover themselves. As long as Gerald is at the helm, this company will be fundamentally flawed IMO.
And great job with massive dilution here, boss. Its looking like a Hong Kong listing. Do you know how much net profit you have to show to move the share price with 500K shares OS? Do the math.
I think some people give too much credit to advisors for their influence. Smart Money/Institutional investors look at the executive, not the advisory board. They can advise, but the CEO's make the decisions.
They are supposed to be the ones who have the vision and plan, and the best ones make a company special. Often their reputations precede them and it brings out the best in each person at that company because they know what the person has done and what he is capable of doing. I just don't see that with Gerald.
OK I'll say it. I'm sure Gerald's a great guy, but investors want a seasoned CEO who has taken biotechs from R+D stage to income producing companies. Not daddy's boy at the helm. A successful CEO with a killer biotech track record would ad .10 alone. And if I hear him say one more time that he played football, or went to Stanford, I'll scream. The best thing Gerald can do for this company is find that CEO. Give Wall St reason to get excited about this company and not just pan it. Investors will line up as much because they believe in the CEO as they do the IP. You have to have BOTH and we don't have it.
Technically speaking today's candlestick was a bearish "shooting star", so there may be more to the downside before it levels off. Filling the gap sort of stuff.
I'd expect dilution soon with only $500k in the kitty.
I think a device that can accurately supply MANF to the brain is something that is a solid addition to treatment of not only Parkinson's but a whole host of end users who require deep brain surgery or treatment. Getting a therapy to the damaged tissue site efficiently is just as important as the therapy itself. Maybe Renishaw will be able to attract interest in AMBS and be a virtual sales rep.
I'm disappointed that they selected Renishaw's system instead of MRI Interventions (MRIC). With MRIC's system, any MRI machine can be used with their guidance system, unlike Reneshaw's which requires it to be done on THEIR machine. I contacted Gerald about MRIC many months ago but I guess it fell on deaf ears. I'd like to know why they went with Renishaw and if they took a look at MRIC.
They didn't have to do a RS like they don't need to do a secondary offering soon, LOL. Question is will they do it before results are announced or after? Doing it before would telegraph that they don't have much confidence in the results, IMO.
Looking at the candlestick for the day, I think the company decided to do the RS EOD seeing it peaked and closed well off that intraday high and would head back down and they wanted to use the momentum for a better price post RS.
I am amazed that so many seem to be surprised that the RS actually happened.
And Gerald is out front of the project faithfully, every day with tin can in hand scrapping together enough funds to keep things moving forward.. LOL.
My thanks.
An equity stake works fine too. They get a share of the price appreciation/profits, and one or two seats on the board so they can have a say and keep abreast of internal developments.
Just trying to think outside the box, which I'm sure BD and any other potential suitor is also doing at this time.
Owning AMBS shares would give BD a stake in the whole company and not just the diagnostics division, which might be their aim. I think we should expand the possibilities that stakeholders may be interested in AMBS's IP and not just in relation to LymPro licensing. The risk/reward to have a stake in LymPro AND MANF should be very attractive at this market cap.
As an option to licensing LymPro, I would not discount the possibility of BD owning part of AMBS down the road. Then they would get a stake in MANF too, and buying AMBS shares would raise the PPS assisting in AMBS's goal of uplisting. It reduces the pressure to do it by a RS. A win-win. Consider ownership of Athelos which is 80% NeoStem, 20% BD.
http://www.neostem.com/assets/Athelos-Fact-Sheet.pdf
Is anyone aware of Toll-like Receptors being mentioned in Dr. Chain's work as far as why amyloids are not being cleared in Alzheimer's? Particularly TLR4? I would think these receptors are not doing its job, but may not be the prime cause of the disease.
It should be clear from 7 clinical failures that clearing amyloids alone is a dead end.